Skip to main content

Table 1 Population characteristics

From: Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers

CharacteristicsTotal population (n = 282)Progression group (n = 20)Progression-free group (n = 262)
Clinical risk groupLow: 197 (69.8%)Low: 9 (45%)Low: 188 (71%)
Intermediate: 83 (29.4%)Intermediate: 10 (50%)Intermediate: 73 (27.9%)
Favorable intermediate: 67 (23%)Favorable intermediate: 8 (40%)Favorable intermediate: 59 (22%)
Unfavorable intermediate: 16 (5.6%)Unfavorable intermediate: 2 (10%)Unfavorable intermediate: 14 (5%)
High: 1 (0.3%)High: 0High: 1 (0.3%)
NA: 1NA: 1 
Radiological risk groupLow: 158 (56%)Low: 9 (45%)Low: 150 (57.3%)
Intermediate: 84 (29.7%)Intermediate: 10 (50%)Intermediate: 75 (28.6%)
Favorable intermediate: 67 (23.7%)Favorable intermediate: 8 (40%)Favorable intermediate: 60 (22.9%)
Unfavorable intermediate: 17 (6%)Unfavorable intermediate: 2 (10%)Unfavorable intermediate: 15 (5.7%)
High: 33 (11.7%)High: 0High: 31 (11.8%)
NA: 7NA: 1NA: 6
Clinical Tumor stageT1c: 226 (80%)T1c: 15 (75%)T1c: 211 (80.5%)
T2a: 50 (17.7%)T2a: 3 (15%)T2a: 47 (17.9%)
T2b: 4 (1.4%)T2b: 1 (5%)T2b: 3 (1.1%)
T2c: 1 (0.3%)T2c: 0T2c: 1 (0.3%)
NA: 1NA: 1 
Radiological Tumor stageT1c: 98 (34.7%)T1c: 5 (25%)T1c: 93 (35.5%)
T2a: 124 (44%)T2a: 10 (50%)T2a: 114 (43.5%)
T2b: 20 (7.1%)T2b: 2 (10%)T2b: 18 (6.9%)
T2c: 32 (11.3%)T2c: 2 (10%)T2c: 30 (11.5%)
T 3a: 1 (0.3%)T 3a: 0T3a: 1 (0.3%)
NA: 7NA: 1NA: 6
Gleason score4: 2 (0.7%)4: 04: 2 (0.8%)
5: 7 (2.5%)5: 1 (5%)5: 6 (2.3%)
6: 213 (75.5%)6: 11 (55%)6: 202 (77.1%)
7 (3 + 4): 52 (18.4%)7 (3 + 4): 7 (35%)7 (3 + 4): 45 (17.2%)
7 (4 + 3): 8 (2.8%)7 (4 + 3): 1 (5%)7 (4 + 3): 7 (2.7%)
Pre-treatment PSA serum level6.4 ng/mL [0.9–17]6.6 [3.76–11.9]6.4 [0.9–17]
Cytoreductive hormone therapyYes: 131 (46.4%)Yes: 12 (60%)Yes: 119 (45.4%)
No: 148 (52.4%)No: 8 (40%)No: 140 (53.4%)
NA: 3 NA: 3
Duration of cytoreductive hormone therapy3 months [0.5–12]2 months [1–8]3 months [0.5–12]
Location of positive biopsy coresBase: 145 (51.4%)Base: 11 (55%)Base: 134 (51.1%)
Midgland: 149 (52.8%)Midgland: 10 (50%)Midgland: 139 (53.1%)
Apex: 131 (46.5%)Apex: 10 (50%)Apex: 121 (46.2%)
NA: 37NA: 3NA: 34
Percentage of positive biopsy coresMedian: 17%Median: 17%Median: 17%
<  50%: 262 (92.3%)<  50%: 17 (92.3%)<  50%: 245 (93.5%)
≥ 50%: 14 (4.9%)≥ 50%: 3 (4.9%)≥ 50%: 11 (4.2%)
NA: 6NA: 0NA: 6
Radiological location of tumorNone: 90 (31.9%)None: 5 (25%)None: 85 (32.4%)
Base: 72 (25.5%)Base: 8 (40%)Base: 64 (24.4%)
Midgland: 112 (39.7%)Midgland: 11 (55%)Midgland: 101 (38.5%)
Apex: 63 (22.3%)Apex: 6 (30%)Apex: 57 (21.8%)
NA: 16NA: 1NA: 15
Disease relapseYes: 20 (7.1%)  
No: 262 (92.9%)  
DeathYes: 2 (0.7%)Yes: 0Yes: 2 (0.7%)
No: 280 (99%),No: 20No: 260 (99%)
Median D90 (Gy)181 [153–189]181 [171–189]181 [153–189]
Median V100 (%)100 [99–100]100 [99,7–100]100 [99–100]
Median V150 (%)49.2 [31.5–64.8]49.2 [33–55]49.2[31–65]
Median D10% urethra196.5 [168.6–240]200 [182–226]196 [168–240]
Median D30% urethra183[102.9–212.2]183 [165–205]182.9 [102–212]
  1. Abbreviations: NA Not available